Medical Device Standards Order (Endotoxin Requirements for Medical Devices) 2018

The Order relies on a small set of tightly-specified concepts that determine applicability, numeric thresholds and testing protocols. The definitions in section 4 and the application in section 5 are primary.

Definitions (s4)

• "endotoxin" is defined as the high molecular weight lipopolysaccharide component of the outer cell wall of gram-negative bacteria and is characterised in the Order as "usually a fever-inducing contaminant in the manufacturing process of medical devices" (s4). The Order therefore frames endotoxin as a manufacturing contaminant hazard.
• "final product" is the medical device or component after all manufacturing processes for the to-be-marketed device, including packaging and, if applicable, sterilisation (s4). Limits in s6 apply to this final product.
• "manufacturer", "medical device", "label" and "default standard" are cross-referenced to the Act or Regulations: "manufacturer" has the same meaning as in s41BG of the Act; "medical device" has the same meaning as in s41BD; "label" has the same meaning as in the Act; and "default standard" has the same meaning as in the Act (s4). The Order therefore relies on those statutory definitions without reproducing them.
• "Regulations" is shorthand for the Therapeutic Goods (Medical Devices) Regulations 2002, as in force from time to time (s4).

Application (s5)

• The Order applies to device kinds listed at s5: implantable devices (s5(a)); devices in direct or indirect contact with cardiovascular, lymphatic systems or cerebrospinal fluid that are labelled sterile and non-pyrogenic (s5(b)); devices contacting the intraocular environment (s5(c)); and any other devices labelled sterile and non-pyrogenic (s5(d)). s5(b) and s5(c) provide non‑exhaustive lists of examples (for instance, catheters, extracorporeal oxygenator tubing, dialysis tubing, intraocular lenses, ophthalmic viscosurgical devices) but the legal coverage is set by the categories and labelling language.
• The Order expressly ties compliance with its sections to compliance with Clause 7.2 of the essential principles in Schedule 1 to the Regulations, in relation to minimising endotoxin risks (preamble). Thus the Order performs a standards-specification function for regulatory compliance under the Act and Regulations.

Endotoxin limits (s6)

• s6(1) sets general final product limits: 20 EU/device for most devices; 2.15 EU/device for devices in contact with cerebrospinal fluid (s6(1)(a)-(b)).
• s6(2) imposes stricter limits for devices contacting the intraocular environment unless a higher EU value is justified: 0.2 EU/device for anterior segment solid devices and 0.2 EU/mL for ophthalmic viscosurgical devices (s6(2)(a)-(b)).
• s6(3) addresses multi-component assemblies: cumulative endotoxin content of each component must not exceed the final-product threshold, except where justified for devices included in s6(2).

Testing and validation requirements (s7)

• s7(1) requires use of the Bacterial Endotoxin Test methodology of a default standard, or an alternative validated method.
• s7(2) requires manufacturers using an alternative method to provide scientifically sound justification and validation evidence for suitability in relation to the device.
• s7(3) requires testing on every batch, except if not practical.
• s7(4) prescribes that, where testing every batch is not practical, manufacturers must establish an appropriate sampling plan, validate it, test incoming raw materials, in-process materials and representative products, and provide a scientifically sound justification addressing the risks of not testing every batch.

The Order thus combines device scope, numeric safety limits, a default test method, and a validation/sampling exception regime. The key levers are labelling (because s5 brings in devices "labelled sterile and non-pyrogenic"), numeric EU thresholds tied to device type, and manufacturer-held validation and justification documentation for alternative methods or sampling regimes (s5; s6; s7).

Primary duty-bearers under the Order are manufacturers, as defined by reference to the Act. Section 4 states that "manufacturer" has the same meaning as in s41BG of the Act, so the legal person responsible for meeting the Order's requirements is the statutory manufacturer (s4). The Order places obligations on manufacturers to ensure final product endotoxin limits and testing regimes align with sections 6 and 7.

Device classes and labelling choices determine which products fall within the standard:

• Manufacturers of implantable medical devices must meet the limits and testing requirements in s6-s7 (s5(a)).
• Manufacturers of devices that contact a person’s cardiovascular system, lymphatic system, or cerebrospinal fluid, and that are labelled sterile and non-pyrogenic, are in scope (s5(b)). The Order gives examples such as fluid pathways of catheters, extracorporeal oxygenator tubing, dialysis tubing, blood administration sets, certain drug delivery catheters, transfusion/infusion assemblies and epidural catheters, as well as liquid medical devices like dialysate and implantable devices like heart valves, vascular grafts and CSF shunt systems (s5(b) examples). The operative criterion is both contact with specified bodily systems and the labelling as sterile and non-pyrogenic.
• Manufacturers of devices contacting the intraocular environment are in scope (s5(c)). Examples provided include ophthalmic viscosurgical devices, intraocular lenses, glaucoma devices, capsular tension rings and accessories used in the intraocular environment.
• The Order also captures "any other devices labelled sterile and non-pyrogenic" (s5(d)); thus manufacturers who label their device as sterile and non-pyrogenic bring the device within the standard even if the device is not explicitly listed elsewhere in s5.

Other parties indirectly affected:

• Suppliers of raw materials and components, because s6(3) requires the cumulative endotoxin content of individual components assembled into the final product not to exceed the final-product threshold unless justified (s6(3)). Where testing every batch is impractical, s7(4)(a) explicitly requires testing for incoming raw materials and in-process materials as part of the validated sampling plan, making upstream suppliers relevant to the manufacturer's compliance documentation.
• Contract testing laboratories and providers of endotoxin test methods, since s7(1) requires use of the Bacterial Endotoxin Test method in a default standard or an alternative validated method; use of alternative methods requires validation evidence from the manufacturer (s7(1)-(2)).
• Regulators charged with administering the Act and the Regulations, because compliance with s6 and s7 is treated as compliance with Clause 7.2 of Schedule 1 to the Regulations (preamble). The Order does not specify enforcement action but the regulatory framework under the Act/Regulations is implicated.

Who does not have direct obligations in the Order:

• The Order does not create explicit obligations for healthcare providers, hospitals, or end users to test or validate devices; obligations are placed on manufacturers (s4; s6-s7).
• The Order does not itself allocate fees, specify reporting pathways to the regulator, or set out administrative enforcement steps. Those matters remain within the Act/Regulations or other instruments (preamble; s3).

Decision points and control:

• Labelling choices by manufacturers determine inclusion for certain device categories (s5(b), s5(d)). Manufacturers therefore decide whether a device is "labelled sterile and non-pyrogenic", which affects whether the Order applies.
• Manufacturers decide whether to use the default Bacterial Endotoxin Test method or an alternative; the latter requires a documented, validated scientific justification (s7(1)-(2)). Manufacturers also decide whether testing every batch is "practical"; if they conclude it is not practical they must put in place a validated sampling plan and risk justification (s7(3)-(4)).

In sum, the Order primarily affects manufacturers of the device kinds listed at s5, their suppliers of components and raw materials, and testing/validation providers. The Order makes manufacturers responsible for documenting validation evidence, sampling plans and scientifically sound justifications where deviations from testing-every-batch or from the default test method are relied upon (s7).

The Order imposes a compact set of mandatory duties on manufacturers and establishes limited procedural rights (principally the right to use validated alternative methods and not to test every batch if justified). Those duties and rights are concentrated in sections 6 and 7 and are framed against the device scope in section 5.

Duties (s6; s7)

• Comply with numerical endotoxin limits for the final product. For most devices this is a duty to ensure endotoxin content is not more than 20 EU per device (s6(1)(a)). For devices in contact with cerebrospinal fluid the duty is to ensure not more than 2.15 EU per device (s6(1)(b)). For intraocular-contact devices the duty is to ensure, unless a higher number of EU is justified, not more than 0.2 EU per device for anterior segment solid devices and not more than 0.2 EU per mL for ophthalmic viscosurgical devices (s6(2)(a)-(b)). Where a final product comprises multiple components, manufacturers must ensure the cumulative endotoxin content of each component does not exceed the overall threshold for the final product, except where justified for intraocular devices in s6(2) (s6(3)).
• Use an appropriate Bacterial Endotoxin Test methodology. The duty in s7(1) is to use the Bacterial Endotoxin Test methodology of a default standard, or a validated alternative method. Where an alternative method is used, the manufacturer must provide a scientifically sound justification and validation evidence for the suitability of that method in relation to the device (s7(2)).
• Test every batch, unless testing every batch is not practical (s7(3)). If testing every batch is not practical, the manufacturer has a duty to:
  • establish an appropriate sampling plan and test incoming raw materials, in-process materials and representative products to ensure the manufacturing process can produce every batch meeting endotoxin limits, and provide validation evidence for that sampling plan and test (s7(4)(a)); and
  • provide a scientifically sound justification addressing the risks for not testing every batch (s7(4)(b)).

Rights or permitted alternatives

• The manufacturer has the right to use an alternative endotoxin test method, but that right is conditional on providing validation evidence and a scientifically sound justification for its use (s7(1)-(2)). The Order therefore allows methodological flexibility provided the alternative is demonstrated to be suitable.
• The manufacturer has the conditional right not to test every batch where it is impractical, but only if it establishes and validates a sampling plan, performs required upstream testing, and documents a risk-based justification (s7(3)-(4)). The right is therefore constrained by documentation and validation duties.

Documentation and justification obligations

• Where the manufacturer relies on an alternative method, or on sampling rather than testing every batch, the Order requires a "scientifically sound justification" and "validation evidence" (s7(2); s7(4)(a)-(b)). The Order does not specify content or format for this evidence, but it does make the obligation explicit and central to any deviation from the default rule.

Interaction with labelling and product definition

• The Order’s applicability to devices "labelled sterile and non-pyrogenic" (s5(b); s5(d)) places an implicit duty on manufacturers to ensure that any label asserting sterility and non-pyrogenicity corresponds to compliance with the Order’s requirements where relevant. The Order uses the Act's definition of "label" (s4), so labelling obligations under the Act and Regulations remain relevant for the accuracy of those claims.

Binding effect and regulatory fit

• The Order states that devices of the covered kinds that comply with sections 6 and 7 are to be treated as complying with Clause 7.2 of the essential principles in Schedule 1 to the Regulations in relation to minimising endotoxin risks (preamble). The practical effect is that compliance with the Order is a route to establishing compliance with the relevant essential principle. The Order does not itself create new criminal offences or civil penalties; it creates mandatory product-level and process-level duties that intersect with the regulatory compliance framework under the Act and Regulations (preamble; s3).

In sum, manufacturers must comply with device-specific numeric limits, use validated test methods (or validate alternatives), test every batch unless not practical and, if not testing every batch, must validate sampling plans and provide scientifically sound risk justifications. The Order grants conditional rights to methodological and sampling flexibility, but only on documented, validated, and scientifically justified grounds.

The Order itself does not set out specific penalties or enforcement mechanisms. It is made under subsection 41CB(1) of the Therapeutic Goods Act 1989 (s3), and it states that devices complying with its sections are to be treated as complying with Clause 7.2 of the essential principles set out in Schedule 1 to the Therapeutic Goods (Medical Devices) Regulations 2002 (preamble). The Order therefore functions as an instrument that specifies a medical device standard within the statutory framework, but it does not enumerate sanctions, inspection powers, notice regimes, or civil penalty provisions.

What the Order does say that bears on enforcement:

• Compliance with sections 6 and 7 is explicitly linked to compliance with an essential principle in the Regulations: the Order declares that devices complying with s6 and s7 are to be treated as complying with Clause 7.2 of Schedule 1 to the Regulations in relation to minimising the risks associated with endotoxin contaminants and residues (preamble). That link indicates how regulatory compliance will be assessed under the essential-principles framework: meeting the Order’s numeric and procedural requirements will be treated as meeting the Clause 7.2 requirement.
• The Order imposes duties on manufacturers to provide validation evidence and scientifically sound justifications for alternative test methods or for not testing every batch (s7(2); s7(4)(a)-(b)). Those documentation obligations create the evidentiary basis on which a regulator would assess conformity; the Order implicitly expects manufacturers to hold the documentation needed to demonstrate compliance.

What the Order does not specify (and the resulting implications):

• The Order does not prescribe inspection, audit, or record-keeping timeframes, nor does it set administrative sanctions such as notices, recalls, remediation directions, or monetary penalties. Any such enforcement steps would need to be pursued under the Act and Regulations, which the Order references but does not reproduce (preamble; s3).
• The Order does not expressly describe how a regulator should evaluate a "scientifically sound justification" or "validation evidence" (s7(2); s7(4)). The absence of procedural criteria gives regulatory assessors discretion to determine sufficiency against the generic phrasing in the Order.

Practical enforcement pathway (as implied by the Order)

• The practical enforcement logic is that regulators will use the Order as the benchmark for Clause 7.2 compliance. A manufacturer who asserts compliance by meeting s6 and s7 would present the validation evidence and scientific justifications required under s7 to a regulator exercising powers under the Act/Regulations. Conversely, a regulator assessing non-compliance with Clause 7.2 could rely on the Order as a standard for determining whether endotoxin limits and testing arrangements are adequate. The Order itself, however, does not create the enforcement machinery or penalties; those remain in the Act/Regulations.

Uncertainty and discretion

• The Order relies on terms such as "scientifically sound justification", "validation evidence", "appropriate sampling plan", and the assessment of whether testing every batch is "practical" (s7(2)-(4)). Because the Order does not elaborate these terms, enforcement will involve judgement calls about what documentation and validation meet the standard. That creates implementation discretion and potential for regulatory variability in enforcement.

In summary, the Order establishes standards and documentation duties that feed into enforcement under the Act and Regulations; it does not itself create penalties or procedural enforcement measures. The Order’s language makes manufacturers’ documentation and validation evidence central to how compliance is assessed, leaving assessment of sufficiency to the regulator under the statutory enforcement framework.

The Order is expressly integrated into the Therapeutic Goods Act 1989 regime and the associated Regulations. The text repeatedly cross-references the Act and the Regulations and positions the Order as a medical device standard under the Act.

Statutory basis and interplay (s3; preamble)

• The Order is made under subsection 41CB(1) of the Therapeutic Goods Act 1989 (s3). The preamble states that the matters in sections 6 and 7 constitute a medical device standard for the kinds of devices in s5 and that medical devices that comply with s6 and s7 are to be treated as complying with Clause 7.2 of the essential principles in Schedule 1 to the Therapeutic Goods (Medical Devices) Regulations 2002 (preamble). The effect is that the Order functions as a standard-setting instrument within the Act’s regulatory architecture.

Cross-references to statutory definitions (s4)

• The Order uses defined terms from the Act and Regulations. "Manufacturer" and "medical device" have the same meanings as in specified sections of the Act (s41BG and s41BD respectively), "label" is used as in the Act, and "default standard" is used as in the Act (s4). This means that, operationally, the Order must be read alongside the Act and Regulations to determine the persons subject to obligations, labelling obligations, and the content of the default standard. The Order does not reproduce those source definitions.

Essential principles and conformity assessment

• By stating that compliance with s6 and s7 is to be treated as compliance with Clause 7.2 of Schedule 1 to the Regulations, the Order gives a concrete route for manufacturers to demonstrate conformity with the essential principle relating to endotoxin minimisation (preamble). Regulators assessing conformity under the Regulations will therefore treat compliance with this Order as satisfying Clause 7.2. The Order does not modify other essential principles or conformity assessment requirements, but it maps this specific hazard-management requirement (endotoxin) to the essential-principles framework.

Interaction with labelling law

• The Order’s applicability hinges in part on labelling: several classes (s5(b); s5(d)) apply only to devices that are "labelled sterile and non-pyrogenic". Because "label" is defined in the Act and labelling obligations and prohibitions are governed by the Act and Regulations, the Order interacts with the broader labelling regime. Manufacturers cannot lawfully label a device "sterile and non-pyrogenic" unless labelling obligations under the Act/Regulations are met; conversely, labelling a device as sterile and non-pyrogenic brings the device within the endotoxin standard’s scope (s5(b)-(d); s4).

Standards and default-method interaction

• s7(1) requires use of the Bacterial Endotoxin Test methodology of a "default standard," or a validated alternative. Because "default standard" is a term with the same meaning as in the Act (s4), the specific test methodology and its provenance depend on what the Act or Regulations designate as the default standard. Thus the Order delegates methodological specificity to other instruments, but the requirement to use the default or a validated alternative is statutory.

Upstream compliance with other regulatory requirements

• s7(4)(a) requires testing for incoming raw materials, in-process materials and representative products where testing every batch is not practical. That requirement dovetails with any GMP (good manufacturing practice) or supplier qualification obligations that exist under the Act/Regulations. The Order does not itself prescribe GMP, but it creates a documentable quality-control and supplier-testing expectation that will interact with obligations in the wider regulatory framework.

Limitations of the Order’s reach

• The Order specifies a medical device standard limited to endotoxin content and testing; it does not purport to govern other safety, labelling, manufacturing or advertising obligations, which remain governed by the Act, Regulations and any other standards or codes. Compliance with sections 6 and 7 is treated as compliance with a specific essential principle, but the Order does not displace or modify other legal obligations.

In short, the Order is an instrument nested within the Act and Regulations. It depends on definitions and references in those instruments (s3; s4), supplies quantitative and procedural requirements that the Regulations will treat as meeting an essential principle (preamble), and links to existing labelling, standards and manufacturing obligations without restating them.

The Order as provided is dated 7 September 2018 and signed by Elizabeth McGrath as delegate of the Minister for Health (preamble). Section 2 states the commencement rule: the Order commences on the day after it is registered on the Federal Register of Legislation (s2). Section 3 records the statutory authority for making the Order: subsection 41CB(1) of the Therapeutic Goods Act 1989 (s3).

The Order text as supplied contains no information about subsequent amendments or variations. There are no amending instruments, repeal clauses, transitional provisions or schedules attached to the supplied text. The Order does not append an amendment history. Therefore, on the basis of the supplied source alone:

• The Order was made on 7 September 2018 (preamble).
• It commences the day after registration on the Federal Register of Legislation (s2).
• It was made under subsection 41CB(1) of the Act (s3).
• No amendments, expiry dates, review clauses, or transitional provisions appear in the supplied text.

If a practitioner needs to know whether the Order has been amended or replaced subsequently, they must consult the Federal Register of Legislation or the consolidated version of the Therapeutic Goods (Medical Devices) Regulations and related instruments. The Order itself does not document any amendment history, nor does it identify any sunset clause or review period within the text provided.

The supplied instrument contains no references to litigation, judicial determinations, tribunal decisions, or case law. The Order itself neither cites nor records any precedent or legal challenge. There are no internal notes about disputes or litigation outcomes.

Consequently, based solely on the Order as supplied:

• There is no litigation history recorded in the text.
• No cases are named, and no judicial commentary or interpretive history is supplied.
• The Order does not include transitional arrangements that reference pending litigation, nor does it reference any regulatory adjudication or tribunal processes.

For any litigation history concerning the Order’s interpretation, enforcement, or application to specific products, a practitioner would need to consult court or tribunal databases, the Federal Register of Legislation for any annotated or consolidated versions that note judicial treatment, or regulator enforcement records. The Order text itself does not supply that material.

The Order is compact, but its structure and language create a number of practical points where compliance risk, interpretation uncertainty, or inadvertent non‑compliance can arise. The following are concrete mechanisms and consequences grounded in the Order’s text.

1. Applicability hinges on labelling language

• The Order applies to devices "labelled sterile and non-pyrogenic" for certain device categories (s5(b); s5(d)). Because labelling is the operative trigger for inclusion, a manufacturer’s decision to use those labelling claims will bring devices into the standard’s scope. Conversely, a manufacturer that avoids those label claims may fall outside the (b)/(d) classes even if the device contacts relevant bodily systems. The Order references the Act’s definition of "label" (s4), so labelling law under the Act/Regulations will apply to the accuracy of such claims. Practically, labelling choices change regulatory obligations.

2. Tight numeric limits for intraocular devices with a justification exception

• s6(2) sets a low threshold (0.2 EU/device; 0.2 EU/mL) for intraocular-contact devices unless "a higher number of Endotoxin Units is justified." The Order does not define what constitutes an acceptable justification or how it must be demonstrated. Manufacturers proposing higher limits therefore must prepare robust, device-specific scientific justification and validation evidence in accordance with s7(2). The absence of statutory content for "justified" leaves assessment to regulators.

3. Cumulative component endotoxin obligation

• Where multiple components are assembled, s6(3) requires that the cumulative endotoxin content of each component must not exceed the overall threshold for the final product, unless justified for devices in s6(2). This can produce upstream testing duties and supplier-management implications, because compliance for a final assembled device cannot rely on one component meeting the threshold if cumulative endotoxin pushes the final product over the limit.

4. "Every batch" baseline but allowance for exception creates a documentation burden

• s7(3) mandates testing on every batch except if impractical. If a manufacturer argues testing every batch is impractical they must meet s7(4)(a)-(b): establish an "appropriate sampling plan", validate it, test incoming raw materials and in-process materials and representative products, and provide a scientifically sound justification addressing risks. The Order does not specify sampling sizes, statistical criteria, or validation protocols, so manufacturers must design and document these elements consistent with scientific norms. That creates a compliance cost in generating and retaining validation studies and justifications.

5. Alternative test-method conditionality

• The Order permits an alternative test method, but only if validated and accompanied by a scientifically sound justification and validation evidence for the method’s suitability in relation to the device (s7(1)-(2)). The Order does not provide objective acceptance criteria for validation evidence, leaving it to the regulator to accept or reject. Manufacturers that change test methods must prepare validation dossiers tailored to device-specific conditions (matrix effects, extraction methods, potential interference).

6. Ambiguity in the term "practical"

• s7(3) and s7(4) hinge on whether testing every batch is "practical". The Order does not define "practical". Manufacturers who take different views on practicability may face regulatory disagreement. Because the Order requires a scientifically sound justification where testing every batch is not practical, differing views on practicability shift the burden to the manufacturer to validate and justify sampling approaches.

7. Reliance on definitions in the Act and Regulations

• Several operative terms are defined by reference to the Act or Regulations (s4). Practitioners must cross-reference those instruments to determine, for instance, who counts as a "manufacturer" and what constitutes a "default standard". Failure to consult the primary definitions risks misidentifying duty-holders or acceptable test standards.

8. No express format for validation evidence or record retention

• The Order mandates "validation evidence" and "scientifically sound justification" (s7(2); s7(4)), but does not prescribe format, retention periods, or submission procedures. Manufacturers should treat these as substantive evidential obligations and maintain robust records, but the Order leaves procedural details to regulators or to good practice.

9. Interaction with device marketing claims and essential-principles compliance

• The Order treats compliance with s6 and s7 as compliance with Clause 7.2 of the essential principles (preamble). If a manufacturer claims compliance with Clause 7.2 by relying on the Order, regulators will expect the documentation required by s7. Inconsistent or incomplete documentation could create regulatory exposure even where numerical limits are met.

10. Examples are non‑exhaustive

• Section 5 provides examples of devices included in the categories (e.g. lists of catheter types, intraocular devices, etc.), but the lists are not exhaustive. Practitioners must therefore assess coverage against the categorical language rather than trying to match to illustrative examples alone (s5).

Each "gotcha" above arises directly from the Order’s language (s4-s7 and preamble). The common compliance risk is documentation: manufacturers must be prepared to demonstrate, with scientifically sound justification and validation evidence, that their methods, sampling plans, and cumulative-component strategies meet the Order’s requirements where they deviate from the default rules.

This section sets out a practical, source-grounded compliance checklist derived from the Order’s operative provisions (s4-s7 and preamble). The focus is on the documents, decisions and tests a manufacturer must put in place to rely on the Order as satisfying Clause 7.2 of the essential principles.

1. Confirm device scope and applicable thresholds (s5; s6)

• Determine whether the device falls within s5’s categories: implantable devices (s5(a)); devices contacting cardiovascular, lymphatic systems or cerebrospinal fluid and labelled sterile and non-pyrogenic (s5(b)); devices contacting the intraocular environment (s5(c)); or any other device labelled sterile and non-pyrogenic (s5(d)).
• Identify the numeric final-product endotoxin limit that applies:
  • Most devices: not more than 20 EU per device (s6(1)(a));
  • Devices in contact with cerebrospinal fluid: not more than 2.15 EU per device (s6(1)(b));
  • Intraocular-contact devices: unless a higher number is justified, 0.2 EU/device for anterior segment solid devices and 0.2 EU/mL for ophthalmic viscosurgical devices (s6(2)(a)-(b)).
• For multi-component products, calculate cumulative endotoxin across components and ensure it does not exceed the final-product threshold (s6(3)).

2. Choose the test method and validate if using alternatives (s7(1)-(2))

• Baseline approach: adopt the Bacterial Endotoxin Test methodology of a default standard (s7(1)). Identify the "default standard" as defined under the Act/Regulations (s4).
• If using an alternative test method, prepare a validation dossier that demonstrates suitability for the specific device matrix. The Order demands a scientifically sound justification and validation evidence for the alternative method (s7(2)). The dossier should, at a minimum, address method sensitivity, specificity, limit of detection/quantitation relevant to the numeric limits, matrix effects, recovery, and comparability to the default method.

3. Batch testing or validated sampling plan (s7(3)-(4))

• Default duty: test every batch for endotoxin content (s7(3)).
• If testing every batch is not practical, develop and validate an "appropriate sampling plan" that covers incoming raw materials, in-process materials and representative products, and demonstrate that the manufacturing process can produce every batch meeting endotoxin limits (s7(4)(a)). Validate the sampling plan with supporting data (e.g. historical process capability, control charts, validated sterilisation/extraction processes).
• Prepare a "scientifically sound justification" addressing the risks of not testing every batch (s7(4)(b)). The justification should tie the sampling plan and process validation to the final-product endotoxin thresholds in s6.

4. Document cumulative component strategy (s6(3))

• For assembled devices, document endotoxin test results for each component and show cumulative endotoxin does not exceed the final-product limit. If a component-level approach is used to support compliance, record extraction and assay approaches used for component testing and any assumptions about additivity of endotoxin contributions (s6(3)).

5. Maintain records and be ready to present validation evidence (s7(2); s7(4))

• Maintain validation evidence, sampling plans, raw-material testing reports, in-process testing data, representative product tests, and scientific justifications. The Order requires these materials where alternative methods or non-batch testing are relied upon (s7(2); s7(4)). While the Order does not set retention periods, these records will be central to regulatory audits, conformity assessments, or if the manufacturer wants to be treated as compliant with Clause 7.2 (preamble).

6. Manage labelling claims carefully (s5(b); s5(d); s4)

• If electing to label devices "sterile and non-pyrogenic", ensure that labelling is consistent with the Act’s definition of "label" and that the device’s endotoxin and sterile-status documentation supports the claim. Labelling choices determine whether the device falls within specified categories in s5 and therefore whether the numerical limits and testing rules apply.

7. Supplier control and incoming material testing (s7(4)(a); s6(3))

• Where components or raw materials could contribute to cumulative endotoxin, establish supplier specifications, certificates of analysis, incoming-material testing, and contractual obligations to ensure supplier-provided endotoxin levels will not compromise final-product compliance. Under s7(4)(a) incoming raw material testing is an explicit component of the validated sampling approach where not testing every batch.

8. Prepare justification for any "higher" endotoxin limit for intraocular devices (s6(2))

• If proposing a higher endotoxin limit for an intraocular device than the 0.2 EU values in s6(2), prepare a device-specific, scientifically sound justification and validation evidence consistent with s7(2). The Order states "unless a higher number of Endotoxin Units is justified" (s6(2)), so the burden is on the manufacturer to justify any departure.

9. Align with the essential-principles conformity strategy (preamble)

• If compliance with Clause 7.2 of the essential principles is to be demonstrated via the Order, ensure that all supporting documentation explicitly maps s6 and s7 compliance to the Clause 7.2 requirements in Schedule 1 to the Regulations. The Order treats compliance with its sections as compliance with Clause 7.2 in relation to endotoxin minimisation (preamble).

10. Plan for regulatory engagement and audit

• Because the Order requires subjective judgements (for instance, whether testing every batch is "practical" or whether a justification is "scientifically sound"), maintain readiness to engage with regulators and to present validation studies, statistical rationale for sampling plans, and risk assessments. While the Order does not prescribe a submission protocol, being able to present a clear evidence trail will be necessary for regulatory review under the Act/Regulations.

Checklist summary

• Confirm device scope under s5.
• Identify applicable numeric limit under s6.
• Choose default test method or validate an alternative under s7(1)-(2).
• Test every batch or validate an appropriate sampling plan with incoming-material/in-process testing and a documented justification under s7(3)-(4).
• Demonstrate cumulative-component compliance under s6(3).
• Maintain validation evidence and justifications for regulatory review.
• Ensure labelling claims are accurate and consistent with the Act’s labelling rules.

Following this compliance pathway aligns operational practice with the Order’s requirements and prepares the manufacturer to be treated as complying with Clause 7.2 of the essential principles under the Regulations, as the Order specifies (preamble).